The estimated Net Worth of Patrick M. Gray is at least $388 Tisíc dollars as of 3 June 2021. Mr. Gray owns over 3,333 units of Dicerna Pharmaceuticals Inc stock worth over $127,387 and over the last 9 years he sold DRNA stock worth over $0. In addition, he makes $260,742 as Independent Director at Dicerna Pharmaceuticals Inc.
Patrick has made over 1 trades of the Dicerna Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 3,333 units of DRNA stock worth $127,387 on 3 June 2021.
The largest trade he's ever made was exercising 3,333 units of Dicerna Pharmaceuticals Inc stock on 3 June 2021 worth over $127,387. On average, Patrick trades about 417 units every 0 days since 2016. As of 3 June 2021 he still owns at least 3,333 units of Dicerna Pharmaceuticals Inc stock.
You can see the complete history of Mr. Gray stock trades at the bottom of the page.
Patrick M. Gray is Independent Director of the Company. Mr. Gray currently serves as a member of the Board of Directors and as Chairperson of the Audit Committee of Tmunity Therapeutics, Inc. Mr. Gray previously served as a member of the Board of Directors and as the Chairperson of the Audit Committee of Civitas Solutions, Inc., from September 2014 to March 2019, Sancilio Pharmaceuticals Company, Inc., from February 2012 through August 2018, and Datto, Inc., from May 2015 through December 2017. Mr. Gray spent over 37 years with PricewaterhouseCoopers LLP (“PwC”) until his retirement in 2009. Mr. Gray is a Certified Public Accountant who spent 25 years as an Audit Partner at PwC. At the time of his retirement, he served as the lead partner for the PwC U.S. firm Corporate Governance Group. Prior to that time, Mr. Gray held various other leadership positions within the firm, including leadership of the Price Waterhouse U.S. High Technology Group. Mr. Gray holds a B.S. in Economics from The Wharton School, University of Pennsylvania. The Nominating and Corporate Governance Committee believes that Mr. Gray’s accounting and financial reporting experience in companies in the industry in which we operate provide him with the qualifications and skills to serve as a member of our Board of Directors.
As the Independent Director of Dicerna Pharmaceuticals Inc, the total compensation of Patrick Gray at Dicerna Pharmaceuticals Inc is $260,742. There are 11 executives at Dicerna Pharmaceuticals Inc getting paid more, with Douglas Fambrough having the highest compensation of $5,048,130.
Patrick Gray is 71, he's been the Independent Director of Dicerna Pharmaceuticals Inc since 2019. There are no older and 13 younger executives at Dicerna Pharmaceuticals Inc.
Patrick's mailing address filed with the SEC is C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over $233,644,011 worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth $36,501,331 . The most active insiders traders include Capital Management, Llc Kol..., Nicole Vitullo a Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,025,674. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth $78,351.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include: